Strategic Business Development Advisory Firm Engaged To Support   New Business Development Activities  Lexaria Awarded 4 New Patents   Kelowna, British Columbia - October 9, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide the following strategic business update.  For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across a number of s ...

 Kelowna, British Columbia – TheNewswire - September 26, 2025 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private ...

Core Insights - Lexaria Bioscience Corp. will participate in the BIO International Convention in Boston from June 16-19, 2025, aiming to advance discussions with potential partners and investors [1][2] Company Overview - Lexaria is a global innovator in drug delivery platforms, specifically through its patented DehydraTECH® technology, which enhances drug absorption and reduces side effects [4] - The company holds 48 granted patents and has additional patents pending worldwide, showcasing a strong intellectual property portfolio [4] Event Participation - The BIO International Convention is the largest biotechnology convention globally, featuring over 1,500 exhibitors and 20,000 attendees, providing a platform for networking and collaboration [2] - Lexaria is arranging one-on-one meetings with corporate leaders in sectors such as weight loss, diabetes, and hypertension, with limited meeting slots still available [3]

Summary of PolyPid (PYPD) Conference Call Company Overview - PolyPid is a clinical-stage biopharmaceutical company focused on drug delivery platforms, specifically the PLEX (polymer lipid encapsulation metrics) technology [2][4] - The company is based in Israel and has capabilities in R&D, regulatory, clinical, and manufacturing [4] PLEX Technology - PLEX allows for the prolonged release of various active pharmaceutical ingredients (APIs) over days to months, significantly longer than competitors who offer 72 to 96 hours [3] - The lead product, DIPLEX 100, is nearing the end of Phase 3 trials, with data expected by the end of the current quarter [3][16] DIPLEX 100 Product Details - DIPLEX 100 combines the PLEX platform with doxycycline to prevent surgical site infections (SSIs) post-abdominal surgeries [7][10] - The product is designed for a 30-day release, aligning with CDC guidelines for SSIs [11] - The total addressable market includes approximately 12 million procedures annually in the U.S. and 8 million in Europe [11][24] Clinical Trials and Results - The Phase 3 trial (SHIELD 2) involves 800 patients comparing DIPLEX 100 with standard IV antibiotics [16][18] - Previous trial (SHIELD 1) showed a 55% reduction in infection rates, 40% reduction in mortality, and 55% reduction in reintervention rates [22] - The trial is designed to meet both FDA and EMEA requirements, with plans for simultaneous filings in the U.S. and Europe [24] Commercial Strategy - The pricing strategy is approximately $600 per vial, with an average of 2.2 vials used per procedure [25] - The company is targeting hospitals directly, as they bear the costs of infections, which can be substantial [26][28] - PolyPid has partnered with Advanced Pharma for European commercialization, valued at over $110 million [30] Financial Position - The company ended the last quarter with $8 million, sufficient to fund operations through Q3 [34] - There are $27 million in warrants tied to trial success, with additional potential funding from commercial partners [35][47] Future Directions - Post-trial, resources will be allocated to other products like OncoPlex, which combines PLEX with chemotherapy for solid tumors [41][42] - The company is exploring additional applications for the PLEX platform in various local treatments [44] Key Takeaways - PolyPid is positioned to address a significant market need with its innovative DIPLEX 100 product, backed by promising clinical trial results and a solid commercialization strategy [11][22][30] - The financial structure appears robust, with multiple avenues for funding and a clear path to market entry following successful trial outcomes [35][47]